Table 1

Baseline demographics and epilepsy characteristics (intent-to-treat population)

Standard AEDs (N=847)VPA stratumCBZ stratum
LEV (N=841)LEV (N=349)VPA-ER (N=347)LEV (N=492)CBZ-CR (N=500)
Age, years, mean±SD40.6±17.840.9±17.835.9±17.838.2±17.944.0±17.042.7±17.5
Age class, n (%)
 ≥16 to <65726 (86.3)734 (86.7)311 (89.1)307 (88.5)415 (84.3)427 (85.4)
 ≥65115 (13.7)113 (13.3)38 (10.9)40 (11.5)77 (15.7)73 (14.6)
Gender, n (%)
 Men466 (55.4)476 (56.2)191 (54.7)202 (58.2)275 (55.9)274 (54.8)
 Women375 (44.6)371 (43.8)158 (45.3)145 (41.8)217 (44.1)226 (45.2)
Number of seizures in the last 2 years*, median (Q1–Q3)3 (2–7)3 (2–8)3 (2–5)3 (2–6)4 (2–10)4 (2–10)
Epilepsy duration years, median (Q1–Q3)0.86 (0.31–2.94)0.99 (0.35–2.74)0.81 (0.28–2.73)1.05 (0.34–2.59)0.94 (0.33–3.06)0.97 (0.35–3.36)
Seizure type n (%)
 Focal seizures543 (64.6)549 (64.8)109 (31.2)101 (29.1)434 (88.2)448 (89.6)
 Primary generalised seizures297 (35.3)290 (34.2)235 (67.3)242 (69.7)62 (12.6)48 (9.6)
 Unclassified only18 (2.1)18 (2.1)11 (3.2)11 (3.2)7 (1.4)7 (1.4)
 Other§8 (1.0)8 (0.9)3 (0.9)3 (0.9)5 (1.0)5 (1.0)
  • * LEV, N=822; standard AEDs, N=831.

  • Time since first seizure, LEV, N=839; standard AEDs, N=844.

  • Patients are counted once in each type of seizure experienced in the past.

  • § Includes seizures unable to clarify at this stage and unknown seizure types.

  • AED, antiepileptic drug; CBZ, carbamazepine; CBZ-CR, controlled-release carbamazepine; LEV, levetiracetam; VPA, sodium valproate; VPA-ER, extended-release sodium valproate; CBZ-CR, controlled-release carbamazepine.